: Oncogenic KRAS sensitizes HME cells to TRAIL, neocarzinostatin and etoposide. The parental human mammary epithelial (HME) cell line and the isogenic cell lines with KI mutations in KRAS (G13D), PI3K (H1047R) and EGFR (delE746A750) were treated with varying doses of izTRAIL alone (upper left panel)
or in combination with 100 nM SM83 (upper right panel) and with 8.8 nM neocarzinostatin (NCS) and 1 µM etoposide (ETO), with or without 100 nM SM83 (lower panel). Viability was tested after 24 h. One representative of two independent experiments is shown. 
